-
Top 10 Immunology Drugs to Watch in 2024
AbbVie
Explore the top 10 best-selling immunology drugs of 2023, including Humira, Dupixent, Stelara, and more. Discover how these innovative therapies are shaping the market, driving clinical breakthroughs, and overcoming competitive challenges.
-
AbbVie Q3 2024 Financial statements
Financial statements
In Q3 2024, AbbVie reported net revenues of $14.460 billion, a 3.8% year-on-year increase. Skyrizi surged by 50.8% to $3.205 billion, offsetting Humira's decline due to generics. Diverse segments, including Oncology and Neuroscience, showed solid growth, while strategic acquisitions.
-
-
FDA approves AbbVie's 24-hour subcutaneous infusion therapy
AbbVie
The FDA has approved AbbVie’s VYALEV (ABBV-951), a 24-hour continuous subcutaneous infusion therapy for advanced Parkinson's disease. This first-of-its-kind treatment, based on levodopa, offers significant improvements in motor fluctuations and prolongs "on" time with fewer complications.
-
-
-
-
浏阳市|
白城市|
观塘区|
万盛区|
龙泉市|
临城县|
东源县|
多伦县|
紫金县|
太保市|
宜丰县|
通海县|
长子县|
开平市|
康乐县|
克什克腾旗|
满洲里市|
安乡县|
连山|
阿拉善右旗|
习水县|
黔南|
奉贤区|
增城市|
类乌齐县|
买车|
静乐县|
浦东新区|
郑州市|
衡山县|
阳山县|
万州区|
宁明县|
文昌市|
揭阳市|
黄石市|
项城市|
随州市|
太康县|
天台县|
灯塔市|